Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258709 | 0.89 | PIK3CA (0.67) | PIK3CASIRT1ABCG2LMNACYP1A2 | |
| SCHEMBL1084043 | 0.85 | CYP1A2 (0.60) | PIK3CAKDM4ELMNACYP1A2CYP3A4 | |
| SCHEMBL14475571 | 0.82 | ALDH1A1 (0.66) | PIK3CASIRT1ABCG2NPSR1LMNA | |
| SCHEMBL258434 | 0.81 | PIK3CA (1.00) | PIK3CAABCG2LMNAHTTCYP1A2 | |
| SCHEMBL14475592 | 0.81 | ALDH1A1 (0.64) | PIK3CAABCG2NPSR1LMNAHTT | |
| SCHEMBL1084163 | 0.81 | CYP1A2 (0.57) | PIK3CAABCG2KDM4ESTAT6NPSR1 | |
| SCHEMBL3748887 | 0.81 | HTT (0.84) | PIK3CAABCG2KDM4ELMNAHTT | |
| SCHEMBL1083909 | 0.78 | HTT (0.71) | PIK3CASIRT1ABCG2KDM4ELMNA | |
| SCHEMBL4098753 | 0.77 | KDM4E (0.57) | SIRT1ABCG2KDM4ESTAT6NPSR1 | |
| SCHEMBL1085578 | 0.76 | CYP1A2 (0.79) | KDM4ENPSR1LMNAHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | claimed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | claimed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | claimed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | claimed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | claimed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | claimed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | claimed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885SIRT1 3977/4885ABCG2 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.